Fred Hutchinson Cancer Research Center Researcher Provides Details of New Studies and Findings in the Area of Cell Therapy (CMV Reactivation and CMV-Specific Cell-Mediated Immunity after Chimeric Antigen Receptor T-Cell Therapy).

A report from the Fred Hutchinson Cancer Research Center in Seattle discusses research findings on cell therapy and cytomegalovirus (CMV) reactivation after chimeric antigen receptor-modified T-cell immunotherapy (CARTx). The study enrolled 72 adult CMV-seropositive CARTx recipients and tested plasma for CMV pre- and post-CARTx. CMV reactivation was detected in 25% of patients, with no end-organ disease observed. Factors associated with CMV reactivation included BCMA-CARTx, corticosteroid use for >3 days, and lower CMV-specific cell-mediated immunity. The researchers suggest considering CMV testing between 2-6 weeks in high-risk CARTx recipients. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)